Holistic Obesity Care in Maryland
Oral Semaglutide 25 mg and Orforglipron for Obesity: New NEJM Insights
Three new NEJM trials highlight the potential of oral GLP-1 therapies for obesity and diabetes. Oral semaglutide 25 mg and orforglipron both achieved double-digit weight loss, far greater than Rybelsus 14 mg. Results from the OASIS-4, ATTAIN-1, and ACHIEVE-1 studies suggest next-generation oral medications may soon rival injectables. These may give patients more flexible, effective, and convenient options for long-term weight management and metabolic health.
Published
MariTide vs Tirzepatide: Similarities and Differences
MariTide and tirzepatide are changing obesity treatment. Both target gut hormones to support weight loss, yet they act differently. Tirzepatide is already approved as a weekly injection, while MariTide is still in trials as a monthly option. Patients may soon have more tailored choices for appetite control and metabolic health.
Published
Once-Monthly MariTide Shows Promise for Weight Loss
MariTide, a once-monthly obesity treatment studied in NEJM, achieved 12–16% weight loss in participants without diabetes and up to 12% in those with diabetes. Patients also saw lower blood sugar levels. Side effects were mostly gastrointestinal and improved with dose escalation. At our Maryland practice, we offer comprehensive obesity and diabetes care, helping patients explore advanced therapies with a balanced viewpoint and personalized care.
Published
CagriSema in Clinical Trials: What Patients Should Know
Two NEJM trials highlight CagriSema, a combination of cagrilintide and semaglutide, as a promising investigational therapy. Patients experienced weight loss exceeding semaglutide alone, with results comparable to tirzepatide. While not FDA approved, the research suggests CagriSema may offer a future option for obesity and diabetes management.
Published
GLP-1 Agonists and Heart Rate: Prevalence and Clinical Significance
GLP-1 agonists like tirzepatide and semaglutide often raise resting heart rate by a few beats per minute. While this is common and usually mild, it may matter in patients with heart rhythm issues, heart failure, or high baseline pulse. This blog explores why it happens, who’s at risk, and how to manage it thoughtfully in clinical care.
Published
Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care
Retatrutide is a triple hormone agonist targeting GLP-1, GIP, and glucagon receptors. Phase 2 trials show up to 24% weight loss, major A1c reduction, and liver fat improvement. This blog reviews trial findings and explains how they may influence our holistic, individualized approach to obesity and diabetes in Montgomery County, Maryland and beyond.
Published
Categorized as Diabetes Care, Dr. Tashko’s Key Clinical Trials, Insights from Dr. Tashko, Obesity Care, Weight Loss
GLP-1 Receptor Agonists: Reducing Inflammation, Improving Health
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well known for lowering blood sugar and promoting weight loss in type 2 diabetes. But their impact doesn’t stop there. Recent evidence highlights their powerful role in reducing inflammation—a key driver behind many chronic diseases.
Published
Categorized as Diabetes Care, GLP1 agonist, Inflammation-Related Conditions, Insights from Dr. Tashko, Obesity Care
Can GLP-1 Agonists Improve Taste Sensitivity?
GLP-1 agonists like Tirzepatide (Mounjaro, Zepbound) and Semaglutide (Ozempic, Wegovy) have become powerful tools in weight management. Their well-known benefits include reducing hunger, curbing cravings, and improving blood sugar regulation. But could they also enhance taste sensitivity and indirectly contribute to healthier eating habits?
Published
The History of BMI: From Social Physics to a Modern Health Tool
The Body Mass Index (BMI) is one of healthcare’s most widely used tools. Doctors, researchers, and policymakers rely on it to assess weight, track health risks, and develop public health strategies. It’s simple, universal, and easy to calculate. But have you ever wondered where it came from? How did a mathematical formula turn into the global standard for measuring body weight?
Published